TAU V337M

Tau protein normally binds to microtubules (cellular scaffolding structures) to stabilize them in neurons. The V337M variant changes valine to methionine at position 337, located in a region that influences tau's behavior. This study used AlphaFold2 to predict the structure of this variant, producing a model with an average confidence (pLDDT) of 55.0, which indicates poor structural definition across most of the protein. The extremely low confidence score suggests this variant exhibits substantial structural disorder, meaning the protein lacks a stable, well-defined 3D shape. Recent research has revealed that tau aggregation into beta-sheet fibrils—the toxic tangles that define Alzheimer's disease and related tauopathies—is a complex process involving multiple structural states [3]. Intrinsically disordered regions in tau are thought to facilitate both its normal microtubule-binding function and its pathological tendency to aggregate under disease conditions. The V337M substitution introduces a longer, sulfur-containing methionine residue where a smaller valine normally resides, potentially altering local flexibility and aggregation propensity. Post-translational modifications and mutations in tau significantly influence its role in Alzheimer's disease neuropathology and cognitive decline [2]. While the computational prediction cannot definitively establish whether V337M promotes aggregation without experimental validation, the high degree of disorder predicted here is consistent with conformational states that may be vulnerable to misfolding. Studies examining tau pathology across neurodegenerative diseases have identified shared molecular mechanisms, including genomic damage patterns in affected neurons [1], suggesting that structural disruptions in tau could have broad consequences for neuronal health. The V337M variant has not been extensively characterized in the literature as a known pathogenic mutation, unlike more commonly studied variants such as P301L. Genetic studies of tau pathology have increasingly employed advanced approaches including rare variant analyses to identify genes and modifications that influence cerebral tau deposition [4]. Without high-confidence structural data or functional studies, it remains uncertain whether V337M directly contributes to disease or represents a rare variant of unclear significance. The predicted disorder may reflect either a pathological state or limitations in modeling this particular sequence variant.